Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status approved; investigational
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 62350-0077; 68682-272; 72189-084; 0168-0432; 22365-121; 51672-4174; 99207-271; 66039-829; 71052-160; 64552-4008; 45802-368; 51552-1538; 62147-0087; 51672-4145; 63629-8818; 68462-536; 51927-0168; 72643-006; 0093-3133; 99207-260; 99207-270; 99207-276; 58175-0397; 62147-0072
UNII P1QW714R7M
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angiopathy24.03.02.007--Not Available
Anogenital warts16.26.01.003; 11.05.07.002; 07.19.04.002; 23.10.01.003; 21.10.03.0040.001712%Not Available
Induration08.01.03.020--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Neurological symptom17.02.05.010--Not Available
Bacterial infection11.02.01.005--Not Available
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.003--Not Available
Infestation11.09.01.001; 23.11.01.002--Not Available
Inflammation10.02.01.089; 08.01.05.0070.003688%Not Available
Ischaemia24.04.02.004--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.001756%
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.001756%
Disease recurrence08.01.03.0500.000439%Not Available
Genital pain21.10.01.008--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Pigmentation disorder23.05.03.0010.000658%Not Available
Skin haemorrhage23.06.07.001; 24.07.01.1030.000439%Not Available
Application site exfoliation23.03.07.007; 12.07.01.022; 08.02.01.022--Not Available
Oral mucosa erosion07.05.06.0090.001185%Not Available
Procedural pain12.02.05.007; 08.01.08.009--Not Available
Skin abrasion23.03.11.018; 12.01.06.010--Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene